文献速递妇科

低剂量仑伐替尼联合托里帕利单抗治疗铂耐药复发性卵巢癌:多中心II期试验(NCT06241105)初步结果

Low-dose lenvatinib plus toripalimab for patients with platinum-resistant recurrent ovarian cancer: preliminary results from a multicenter, phase II trial (NCT06241105).
PubMed 文献 · Gynecol Oncol · 2025-07-04

该多中心单臂II期试验初步纳入33例复发性铂耐药卵巢癌患者,接受低剂量仑伐替尼(每日8或12 mg)联合托里帕利单抗(240 mg,每三周一次)。中位无进展生存期5.0个月(95%CI 3.8-6.2),中位总生存期13.3个月(95%CI 12.4-14.2),客观缓解率27%(95%CI 13%-46%),疾病控制率54%(95%CI 36%-72%)。治疗相关不良事件发生率97%(3级39%;无4-5级),12%患者需减量。

要点

  • 低剂量仑伐替尼联合托里帕利单抗在经多线治疗的复发性铂耐药卵巢癌中显示初步疗效和耐受性。
  • 中位无进展生存期5.0个月(95%CI 3.8-6.2),中位总生存期13.3个月(95%CI 12.4-14.2)。
  • 客观缓解率27%(95%CI 13%-46%),疾病控制率54%(95%CI 36%-72%)。

核心结论

  • 低剂量仑伐替尼联合托里帕利单抗在经多线治疗的复发性铂耐药卵巢癌中显示出鼓舞人心的疗效和耐受性,但需完成入组以确认结果。

研究设计与样本

  • 多中心、单臂II期试验(NCT06241105),初步分析纳入33例复发性铂耐药卵巢癌患者。
  • 患者接受低剂量仑伐替尼(每日8或12 mg)联合托里帕利单抗(240 mg,每三周一次)。
  • 主要终点为无进展生存期(PFS),次要终点包括客观缓解率(ORR)、缓解持续时间(DOR)、疾病控制率(DCR)、总生存期(OS)和安全性。

主要发现

  • 中位(95%CI)PFS和OS分别为5.0个月(3.8-6.2)和13.3个月(12.4-14.2)。
  • 首个周期后CA125下降≥50%的患者PFS更长(7.9 vs 3.7个月)。
  • ORR为27%(95%CI 13%-46%),DCR为54%(95%CI 36%-72%),中位DOR为4.4个月(范围2.1-≥17.4)。
  • 治疗相关不良事件发生率97%(3级39%;无4-5级),4例(12%)患者需仑伐替尼减量,治疗中断率和终止率分别为42%和12%。
  • 试验治疗进展后接受铂再挑战的患者似乎恢复了铂敏感性。

局限性

  • 原文为初步分析结果,需完成入组以确认这些结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Platinum-resistant ovarian cancer (PROC) remains a therapeutic challenge. While immune checkpoint inhibitor plus lenvatinib demonstrates potential efficacy in ovarian cancer, the standard 20 mg lenvatinib dosage causes significant adverse events leading to treatment disruption. We present preliminary results of a multicenter, single-arm phase II trial evaluating low-dose lenvatinib plus toripalimab for recurrent PROC. METHODS: Patients with recurrent PROC received low-dose lenvatinib (8 or 12 mg daily) and toripalimab (240 mg, every three weeks). Primary endpoint was progression-free survival (PFS). Second endpoints included objective response rate (ORR), duration of response (DOR), disease control rate (DCR), overall survival (OS), and safety. RESULTS: Thirty-three patients were enrolled at preliminary analysis. 91 % were platinum-resistant, and 9 % were platinum-refractory, with a median of 3 prior therapy lines (range 1-12). Median (95 % CI) PFS and OS were 5.0 months (3.8-6.2) and 13.3 months (12.4-14.2), respectively. Patients with CA125 decrease ≥50 % after the first cycle had longer PFS (7.9 vs 3.7 months). The ORR was 27 % (95 % CI 13 %-46 %) and DCR was 54 % (95 % CI 36 %-72 %). Median DOR was 4.4 months (range 2.1- ≥ 17.4). Treatment-related adverse events occurred in 97 % of patients (39 % grade 3; no grade 4-5). Four (12 %) patients required lenvatinib dose reduction, with treatment interruption and discontinuation rates of 42 % and 12 %, respectively. Patients who underwent platinum rechallenge following progression on trial treatment appeared to regain platinum sensitivity. CONCLUSIONS: Low-dose lenvatinib plus toripalimab demonstrated encouraging efficacy and tolerability in patients with heavily pretreated, recurrent PROC. Completed accrual is needed to confirm these results.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Su H, Shang X, Liu H, et al. Low-dose lenvatinib plus toripalimab for patients with platinum-resistant recurrent ovarian cancer: preliminary results from a multicenter, phase II trial (NCT06241105). Gynecol Oncol. 2025. PMID: 40616958. doi:10.1016/j.ygyno.2025.06.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。